Go to the list of all blogs
Anna G's Avatar
published in Blogs
May 21, 2023
Analyzing the Downturn: Unveiling the Story Behind Hims & Hers Health's (HIMS) -12.69% Monthly Descent

Analyzing the Downturn: Unveiling the Story Behind Hims & Hers Health's (HIMS) -12.69% Monthly Descent

Unlocking the Power of Artificial Intelligence to Make Trading Decisions with Tickeron's AI Robots.

In the competitive realm of healthcare and personal care, Hims & Hers Health (HIMS) faced a challenging month, witnessing a significant downturn of -12.69% and closing at $9.77 per share. This blog post aims to unravel the story behind Hims & Hers Health's notable setback, shedding light on the broader trends within the Household/Personal Care Industry. Join us as we dive into the analysis, examining the factors that contributed to the company's descent and exploring the market landscape that influenced its performance.

Understanding the Household/Personal Care Industry: To gain insights into Hims & Hers Health's performance, it is essential to understand the dynamics of the Household/Personal Care Industry. Our analysis of 95 stocks in this sector reveals that 47.37% exhibited an Uptrend, while 52.63% experienced a Downtrend. This industry overview sets the stage for comprehending the specific challenges and opportunities faced by Hims & Hers Health.

Factors Impacting Hims & Hers Health's Descent: Multiple factors may have influenced Hims & Hers Health's -12.69% monthly decline. Market conditions, competitive pressures, regulatory changes, or internal operational factors could have played a role in the company's setback. By examining these factors in detail, we can gain valuable insights into the circumstances that impacted Hims & Hers Health's performance.

Navigating the Landscape of Household/Personal Care: As investors evaluate the impact of Hims & Hers Health's descent, it becomes crucial to navigate the Household/Personal Care Industry with a discerning eye. Understanding the current market outlook, identifying potential opportunities, and assessing the risks associated with the sector are vital considerations for informed decision-making. This blog post provides valuable insights and strategies to help investors navigate the ever-evolving landscape of the Household/Personal Care Industry amidst Hims & Hers Health's downturn.

Hims & Hers Health's -12.69% monthly descent serves as a reminder of the volatility and challenges inherent in the Household/Personal Care Industry. By analyzing the broader market trends and uncovering the factors that influenced Hims & Hers Health's performance, investors can gain a comprehensive understanding of the landscape. In an industry that continues to evolve rapidly, staying informed, adapting to market conditions, and identifying potential opportunities while managing risks are crucial for investors seeking success in the Household/Personal Care sector.

Related Ticker: HIMS

Momentum Indicator for HIMS turns positive, indicating new upward trend

HIMS saw its Momentum Indicator move above the 0 level on May 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for HIMS just turned positive on May 29, 2026. Looking at past instances where HIMS's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

HIMS moved above its 50-day moving average on May 27, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HIMS crossed bullishly above the 50-day moving average on June 01, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HIMS broke above its upper Bollinger Band on June 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for HIMS entered a downward trend on May 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.970) is normal, around the industry mean (146.073). P/E Ratio (57.137) is within average values for comparable stocks, (97.164). Projected Growth (PEG Ratio) (2.155) is also within normal values, averaging (1.600). HIMS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.032). P/S Ratio (3.090) is also within normal values, averaging (96.656).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.04B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 1%. For the same Industry, the average monthly price growth was 22%, and the average quarterly price growth was 8%. GELS experienced the highest price growth at 198%, while OPTH experienced the biggest fall at -27%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 119%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -57%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 66
Price Growth Rating: 59
SMR Rating: 87
Profit Risk Rating: 84
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
HIMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a company, which is involved in real estate investment trusts

Industry PharmaceuticalsGeneric

Profile
Details
Industry
N/A
Address
2269 Chestnut Street
Phone
+1 415 851-0195
Employees
658
Web
https://www.forhims.com
Interact to see
Advertisement
Quanta Services (PWR), a leader in infrastructure solutions for electric power, renewables, and communications, has demonstrated resilient performance in recent trading sessions. The stock has maintained upward momentum amid broader market cycles favoring energy and infrastructure sectors, driven by increasing demand for grid modernization and sustainable projects. Trading near its 52-week highs, PWR reflects positive investor sentiment, with a market capitalization exceeding $68 billion and a trailing P/E ratio around 68. Volatility has been moderate, influenced by sector-wide catalysts, positioning the company as a growth-oriented pick in the industrial space. This stock analysis highlights PWR's ability to capitalize on long-term trends in energy transition.
Teradyne (TER), a leader in automated test equipment and industrial robotics, has demonstrated resilient performance amid a favorable semiconductor market cycle. In recent weeks, the stock has maintained upward traction, outperforming broader indices like the Nasdaq, supported by AI-driven demand for chip testing solutions.
Curtiss-Wright Corporation (CW) has demonstrated resilience in recent trading sessions, navigating a period of moderate volatility within the aerospace and defense sector. The stock has shown upward momentum over the latest market cycle, supported by strong demand in commercial and military applications.
CrowdStrike Holdings (CRWD) has shown resilience in the cybersecurity sector amid broader market cycles, with shares experiencing moderate pullbacks in recent weeks following strong year-to-date gains. The stock trades near its upper range, reflecting investor optimism in AI-driven security innovations and platform adoption.
Arista Networks (ANET) has demonstrated resilience in recent trading sessions amid fluctuating tech market conditions. The stock has navigated broader sector headwinds, including competition in cloud networking and varying demand from hyperscale clients.
Galaxy Digital Holdings Ltd. (GLXY), a leading player in digital assets and blockchain investment, has shown resilience in recent trading sessions amid cryptocurrency market dynamics. The stock has navigated volatility driven by Bitcoin's price fluctuations, reflecting broader sector sentiment.
In the ever-shifting healthcare sector, CVS Health (CVS) and UnitedHealth Group (UNH) represent two powerhouse approaches: CVS as a retail pharmacy giant with integrated insurance and services, and UNH as a leading health insurer with diversified operations.
In the competitive retail landscape, American Eagle Outfitters (NYSE: AEO) is showing signs of robust upward potential as it navigates a strong 2025 performance.
In the dynamic world of satellite communications and broadband services, EchoStar Corporation (NASDAQ: SATS) has captured investor attention with a notable technical breakthrough. On December 8, 2025, the stock's 10-day moving average crossed above its 50-day moving average, signaling the onset of a bullish upward trend.
In an era where global investors demand instant access to markets, major players in the financial world are racing to extend trading hours beyond the traditional 9:30 a.m. to 4 p.m. ET window. This push is driven by surging foreign holdings of U.S. equities, which hit $17 trillion last year, and the growing appetite for nonstop trading in a 24/7 digital economy.
In the resilient gold mining sector, IAMGOLD Corporation (NYSE: IAG) has demonstrated an extraordinary uptrend throughout 2025, capitalizing on rising gold prices and operational milestones.
Within the rapidly evolving automotive retail landscape, Carvana Co. (NYSE: CVNA) has emerged as one of 2025’s standout performers. Once viewed as a highly volatile name, the company has transformed into a market leader as demand for online vehicle purchasing accelerates
Microsoft (MSFT) emerges as the AI-favored stock in 2025, outperforming Apple (AAPL) with a 16% year-to-date gain, compared to Apple’s 10% rise. The advantage stems from Microsoft’s deeper enterprise AI integration, accelerating cloud growth, and scalable software ecosystem.
ExxonMobil (XOM) emerges as the AI-preferred energy stock in 2025, posting a 10% year-to-date gain compared with Chevron’s (CVX) 2% increase. Stronger upstream production, exposure to high-growth assets, and expanding low-carbon initiatives support XOM’s momentum. Tickeron’s AI models signal continued upside for XOM, while CVX shows signs of overbought conditions and elevated downside risk.
Tesla (TSLA) emerges as the AI-preferred EV stock in 2025, posting a 19% year-to-date gain, while BYD (BYDDY) has declined 82%, reflecting diverging momentum across the global EV market. Tickeron’s AI trading bots indicate strong bullish conditions for TSLA, supported by positive momentum signals, whereas BYDDY shows sustained bearish trends.
Broadcom (AVGO) emerges as the AI-preferred semiconductor stock in 2025, posting a 48% year-to-date gain, compared with 37% for NVIDIA (NVDA), supported by stronger diversification across networking, infrastructure, and custom AI chips.
- Bio-Techne carries a “Moderate Buy” consensus from 13 analysts, with an average price target of $70.58, implying about 15% upside. - Recent positive revisions include TD Cowen (Oct. 14, target raised from $65 to $70, Strong Buy), Evercore ISI (Oct. 7, $60 to $72, Buy), and RBC -
Skyworks Solutions (SWKS) has traded unevenly in recent weeks as investors digest shifting sector dynamics and company-specific guidance. The stock has moved into a consolidation phase following broader semiconductor rotations, with optimism in diversified end markets offset by ongoing pressure in mobile.
Seagate Technology (STX) has emerged as one of the standout performers of 2025, powered by explosive demand for data storage tied to artificial intelligence workloads. As hyperscalers expand cloud and AI infrastructure, Seagate’s high-capacity hard drives have become essential, pushing the stock sharply higher and keeping investor attention firmly locked on upcoming earnings.